Pioglitazone alters monocyte populations and stimulates recent thymic emigrants in the BBDZR/Wor type 2 diabetes rat model

Diabetology & Metabolic Syndrome
Bradley T GaoVanessa M Morales-Tirado

Abstract

Type 2 diabetes is commonly characterized by insulin deficiency and decreased sensitivity of insulin receptors, leading to a chronic state of hyperglycemia in individuals. Disease progression induces changes in the immune profile that engenders a chronic inflammatory condition. Thiazolidinedione (TDZ) drugs, such as Pioglitazone (Pio), aid in controlling disease symptoms. While the mechanisms by which Pio controls hyperglycemia are beginning to be understood, relatively little is known about the effects of Pio on suppression of the systemic immune phenotype, attributed to visceral adipose tissue and macrophages. Here, we utilize the recently developed BBDZR/Wor type 2 diabetes rat model to test our hypothesis that a selective in vivo growth of CD3(+)T cells in the spleen contributes to the increase in T lymphocytes, including Tregs, independent of visceral adipose tissue. We investigated the systemic effects of Pio on multifactorial aspects of the disease-induced immune phenotype both in vivo and in vitro in normal, non-diabetic animals and in disease. Our work revealed that Pio reversed the lymphopenic status of diabetic rats, in part by an increase in CD3(+) T lymphocytes and related subsets. Moreover, we found evidence that ...Continue Reading

References

Aug 1, 1992·Diabetes Care·C A Hofmann, J R Colca
Mar 1, 1988·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·Y SugiyamaT Fujita
Jan 1, 1987·European Journal of Immunology·E SeverinsonT Honjo
May 1, 1997·Immunity·D J FowellR M Locksley
Dec 22, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K UchimuraH Nawata
Sep 18, 2002·The Journal of Clinical Investigation·Kathrin MaedlerMarc Y Donath
Jan 11, 2003·Science·Shohei HoriShimon Sakaguchi
Mar 4, 2003·Nature Immunology·Jason D FontenotAlexander Y Rudensky
Mar 4, 2003·Nature Immunology·Roli KhattriFred Ramsdell
Dec 18, 2003·The Journal of Clinical Investigation·Stuart P WeisbergAnthony W Ferrante
Dec 18, 2003·The Journal of Clinical Investigation·Haiyan XuHong Chen
Mar 22, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Philippe PoussierSheela Ramanathan
Jun 21, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ryan W HickGregory D Sempowski
Jul 11, 2006·The Journal of Clinical Investigation·Steven E ShoelsonAllison B Goldfine
Mar 21, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Elizabeth A WohlfertRobert B Clark
Apr 5, 2007·European Journal of Immunology·Gyöngyike MajaiLászló Fésüs
Oct 27, 2007·Investigative Ophthalmology & Visual Science·Robert J Walker, Jena J Steinle
Feb 15, 2008·Diabetes Care·Marc Y DonathJan A Ehses
Jun 28, 2008·Blood·Siegfried Kohler, Andreas Thiel
Dec 21, 2010·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Vanessa Morales-TiradoJanice M Riberdy
Jan 15, 2011·Nature Reviews. Immunology·Marc Y Donath, Steven E Shoelson
Aug 26, 2011·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Kimberly A KasowJanice M Riberdy
Mar 27, 2012·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Makoto FujimotoYutaka Shimada
Dec 25, 2012·The American Journal of Hospice & Palliative Care·Ferraz GonçalvesLaura Teixeira
Mar 13, 2013·Nutrición hospitalaria·F de Carvalho VidigalR de Cássia Gonçalves Alfenas
Mar 16, 2013·Current Diabetes Reports·Eric Lontchi-YimagouAndre Pascal Kengne
Mar 21, 2013·Best Practice & Research. Clinical Obstetrics & Gynaecology·Gul Bano

❮ Previous
Next ❯

Methods Mentioned

BETA
Protein Assay
flow cytometry

Software Mentioned

GraphPad
FlowJo

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here